Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis

Table 4 Predictors of positive immune response (seroconversion)*

	P-value	OR	95% CI
Age (years)	<0.001	0.96	0.94-0.98
Sex (male/female)	0.984	0.99	0.57-1.73
Diagnosis (RA/SpA)	0.361	0.77	0.43-1.36
Time between vaccination and retrieving of blood samples (months)	0.334	0.97	0.91-1.03
Current smoking (yes/no)	0.025	0.47	0.24-0.91
Pre-vaccination antibody titers	0.001	0.97	0.94-0.99

Analysis was performed using a multivariate logistic regression model. CI, confidence interval; HI, hemagglutination inhibition; OR, odds ratio.
* Seroconversion is defined as prevaccination titres <10 and postvaccination HI ≥40 or a ≥4-fold increase in HI titers.

ISSN: 1478-6362